MARS and treatment of hepatic encephalopathy;MARS y el tratamiento de la encefalopatía hepática

Gastroenterologia y Hepatologia

Volumn 28, Issue 2, 2005, Pages 100-104

  Blei, A T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALBUMIN DIALYSIS; DIALYSIS; FEMALE; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; LIVER FAILURE; MALE; PROGNOSIS; REVIEW; SYSTEMIC THERAPY; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 14344262025     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13070709     Document Type: Article

References (29)

1. Conn HO. Assessment of mental state. En: Conn HO, Lieberthal MM, editors. The hepatic coma syndromes and lactulose. Baltimore: Williams & Wilkins, 1979; p. 169-88.
2. Sen S, Williams R, Jalan R. The pathophysiology basis of acute-on-chronic liver failure. Liver 2002;22(Suppl):5-13.
3. Ruiz del Árbol L, Urman J, Fernández J. Systemic, renal and hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;38:1210-8.
4. Demetriou A, Brown R, Busuttil RW, Fair J, McGuire B, Rosenthal P, et al. Prospective, randomized, multi-center, controlled trial of the HepatAssist system in treating acute liver failure [in press]. Ann Surg, 2004.
5. Ferenci P, Lockwood A, Mullen K, Tartar R, Weissenborn K, Blei AT. Hepatic encephalopathy -definition, nomenclature, diagnosis, and quantification. Hepatology 2002;35:716-21.
6. Gyr K, Meier R, Haussler J, Bouletreau P, Fleig WE, Holstege A, et al. Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomized, placebo controlled multicentre study. Gut 1996;39:319-24.
7. Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe alcoholic hepatitis. J Hepatol 2003;38:24-31.
8. Novelli G, Rossi M, Pretagostini R, Poli L, Novelli L, Berloco P, et al. MARS experience in 34 cases of acute liver failure. Liver 2002;22(Suppl):43-7.
9. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artficial and bioartificial support systems for acute and acute-on-chronic failure: a systematic review. JAMA 2003;289:217-22.
10. Heeman U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002; 36:949-58.
11. Fraser CL, Arieff AI. Metabolic encephalopathy as a complication of renal failure: mechanisms and mediators. New Horiz 1994;2:518-26.
12. Schiodt FV, Clemmesen JO, Hansen BA, Larsen FS. Cerebral edema due to hemodialysis in paracetamol-induced fulminant hepatic failure. Scand J Gastroenterol 1995;30:927-8.
13. Butterworth RF. Molecular neurobiology of acute liver failure. Semin Liver Dis 2003;23:251-8.
14. Vaquero J, Chung C, Cahill M, Blei AT. Pathogenesis of hepatic encephalopathy in acute liver failure. Semin Liver Dis 2003; 23:259-69.
15. Córdoba J, Blei AT, Mujais S. Determinants of ammonia clearance by hemodialysis. Artif Organs 1996;20:800-3.
16. Mitzner S, Loock J, Peszynski P, Klammt S, Majcher-Peszynska J, Gramowski A. Metab Brain Dis 2002;17:463-75.
17. Yurdaydin C, Hortnagl H, Steindl P, Zimmermann C, Pifl C, Singer EA. Increased serotoninergic and noradrenergic activity in hepatic encephalopaty in rats with thioacetamide-induced acute liber failure. Hepatology 1990;12:695-700.
18. Vorobioff J, García-Tsao G, Groszmann R, Aceves G, Picabea E, Villavicencio, et al. Long-term hemodynamic effects of ketanserin, a 5-hydroxytryptamine blocker, in portal hypertensive patients. Hepatology 1989;9:88-91.
19. Steindl PE, Finn B, Bendok B, Rothke S, Zee PC, Blei AT. Disruption of the diurnal rhythm of plasma melatonin in cirrhosis. Ann Intern Med 1995;15:274-7.
20. Rose C, Butterworth RF, Zayed J, Normandin L, Todd K, Michalak A, et al. Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. Gastroenterology 1999;117:640-4.
21. Sen S, Felldin M, Steiner C, Larson B, Gillett GT, Olausson M, et al. Albumin dialysis and molecular adsorbents recirculating system (MARS) for acute Wilson's disease. Liver Transpl 2002; 8:962-7.
22. Jones EA, Basile AS. Does ammonia contribute to increased GABA-ergic neurotransmission in liver failure? Metab Brain Dis 1998;13:351-60.
23. Goulenok C, Bernard B, Cardranel JF, Thabut D, Di Martino V, Opolon P, et al. Flumazenil versus placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2002;16:361-72.
24. Blei AT. Infection, inflammation and hepatic encephalopathy, synergism redefined. J Hepatol 2004;40:327-30.
25. Awad SS, Sawada S, Soldes OS, Rich PB, Klein R, Alarcon WH, et al. Can the clearance of tumor necrosis factor alpha and interleukin 6 be enhanced using an albumin dialysate hemodiafiltration system? ASAIO J 1999;45:47-9.
26. Guevara M, Bru C, Ginès P, Fernández-Esparrach G, Sort P, Bataller R, et al. Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology 1998;28:39-44.
27. Schmidt LE, Wang LP, Hansen BA, Larsen FS. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial. Liver Transpl 2003;9:290-7.
28. Schmidt LE, Svendsen LB, Sorensen VR, Hansen BA, Larsen FS. Cerebral blood flow velocity increases during a single treatment with the molecular adsorbents recirculating system in patients with acute on chronic liver failure. Liver Transpl 2001;7:709-12.
29. Kamath PS. Is there life in MARS? Hepatology 2002;36: 1017-9.